European regulators have good news for Amgen on cancer drugs
One of the world’s most expensive cancer drugs got conditional approval from European regulators on Sept. 25. Europeans granted Thousand Oaks-based Amgen conditional approval of its rare blood cancer drug Blincyto and gave a positive evaluation of Amgen’s multiple-myeloma drug Kyprolis. Blincyto is an immunotherapy that is designed to treat a rare form of leukemia Read More →
St. John’s Pleasant Valley Hospital in Camarillo building new tower
St. John’s Pleasant Valley Hospital in Camarillo will hold a groundbreaking ceremony at 3:30 p.m. Sept. 24 for a three-story, 75,000-square-foot tower. The $80 million addition, which will be attached to the emergency department, will occupy the plot of land where the old emergency department parking lot now sits. The first floor of the new Read More →
Amgen cancer drug Kyprolis to get expedited review from FDA
An experimental multiple myeloma treatment using Amgen’s Kyprolis will get an expedited review from the U.S. Food and Drug Administration. The FDA said it will use an expedited review process to review a multiple-myeloma treatment using Kyprolis and the genric drug dexamethasone. On July 23, Amgen submitted additional data to the FDA which compared this Read More →
Westlake Village-based Kythera Biopharmaceuticals reports second quarter loss
Westlake Village-based Kythera Biopharmaceuticals missed analyst estimates when it released second quarter earnings on Aug. 6. Kythera lost $1.44 per share, missing analyst estimates of a loss of $1.10 per share. For the quarter, Kythera lost $37.2 million, compared to $19.5 million during the second quarter of 2014. On June 17, Allergan announced that it Read More →
